Using MAPK synergies by co-targeting the AKT, MTOR, and PIK3CA has shown promise in other HNSCC studies.25,26 We also observe a statistically significant increase in AKT phosphorylation at 72 hours. The gene discussed is AKT1; the disease is head and neck squamous cell carcinoma.